These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 11522648

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells.
    Wickström SA, Alitalo K, Keski-Oja J.
    Cancer Res; 2002 Oct 01; 62(19):5580-9. PubMed ID: 12359771
    [Abstract] [Full Text] [Related]

  • 3. Endostatin regulates endothelial cell adhesion and cytoskeletal organization.
    Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L.
    Cancer Res; 2002 Apr 01; 62(7):1944-7. PubMed ID: 11929807
    [Abstract] [Full Text] [Related]

  • 4. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
    Salasznyk RM, Zappala M, Zheng M, Yu L, Wilkins-Port C, McKeown-Longo PJ.
    Matrix Biol; 2007 Jun 01; 26(5):359-70. PubMed ID: 17344041
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor.
    Prager GW, Breuss JM, Steurer S, Olcaydu D, Mihaly J, Brunner PM, Stockinger H, Binder BR.
    Circ Res; 2004 Jun 25; 94(12):1562-70. PubMed ID: 15131009
    [Abstract] [Full Text] [Related]

  • 6. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ, Lee SW, Dichek DA, Ellis V.
    J Pept Sci; 2000 Sep 25; 6(9):432-9. PubMed ID: 11016879
    [Abstract] [Full Text] [Related]

  • 7. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
    Schaefer BM, Stark HJ, Fusenig NE, Todd RF, Kramer MD.
    Exp Cell Res; 1995 Oct 25; 220(2):415-23. PubMed ID: 7556451
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug 25; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

  • 10. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K.
    J Lab Clin Med; 2004 Aug 25; 144(2):69-77. PubMed ID: 15322501
    [Abstract] [Full Text] [Related]

  • 11. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 25; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
    Reinartz J, Link J, Todd RF, Kramer MD.
    Exp Cell Res; 1994 Oct 25; 214(2):486-98. PubMed ID: 7925643
    [Abstract] [Full Text] [Related]

  • 14. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM, Strickland S.
    J Cell Physiol; 1997 May 25; 171(2):217-25. PubMed ID: 9130470
    [Abstract] [Full Text] [Related]

  • 15. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A, Brun P, Sartori MT, Cortivo R, Dedominicis C, Saggiorato G, Abatangelo G, Secchi AG.
    Invest Ophthalmol Vis Sci; 2005 Apr 25; 46(4):1364-70. PubMed ID: 15790903
    [Abstract] [Full Text] [Related]

  • 16. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD, Tomaso H, Mengele K, Schilling D, Bayer C, Stadler P, Schmitt M, Molls M.
    Oncol Rep; 2007 May 25; 17(5):1259-68. PubMed ID: 17390074
    [Abstract] [Full Text] [Related]

  • 17. Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.
    Chazaud B, Bonavaud S, Plonquet A, Pouchelet M, Gherardi RK, Barlovatz-Meimon G.
    Exp Cell Res; 2000 Aug 01; 258(2):237-44. PubMed ID: 10896774
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Urokinase anchors uPAR to the actin cytoskeleton.
    Bernstein AM, Greenberg RS, Taliana L, Masur SK.
    Invest Ophthalmol Vis Sci; 2004 Sep 01; 45(9):2967-77. PubMed ID: 15326109
    [Abstract] [Full Text] [Related]

  • 20. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
    Mohanam S, Chandrasekar N, Yanamandra N, Khawar S, Mirza F, Dinh DH, Olivero WC, Rao JS.
    Oncogene; 2002 Nov 07; 21(51):7824-30. PubMed ID: 12420219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.